Insight into the profibrinolytic activity of dermatan sulfate: Effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators

Castañon, María Mercedes; Gamba, Cecilia; Kordich, L

doi:10.1016/j.thromres.2006.12.014

Cited by 7 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein electrophoresis is a general technology for detecting the action of urokinase on plasminogen, 24 and was carried out in a vertical slab gel unit DYY-6C. The separation gel (sodium dodecyl sulphate, GE healthcare, USA) was 10 cm high, and had a total concentration of 12%, with a crosslinking of 4% and contained 10% of glycerol (GE healthcare, USA).…”

Section: V-7 Effect Of Cippc On Electrophoresis Of Uk and Plasminogenmentioning

confidence: 99%

From Cerius2 based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors

et al. 2011

View full text Add to dashboard Cite

Antifibrinolytic therapy during major complex surgery could reduce blood loss and allogeneic transfusion. Novel antagonists of the plasminogen activator and the corresponding model system are of clinical importance. In this paper (1S,2'S,3S)-1-[2-(S)-carboxylindolemethylenemethineaminoeth-1-yl]-2,3,4,5-tetrahydropyrolo[1,2:1,6]pyrazino[3,4:2,3]-1,2,3,4-tetrahydrocarboline-2,5-dione (CIPPC) was presented as a novel antagonist of plasminogen activator, and its blood coagulation and action mechanism were investigated by using a model system which consisted of a mouse-tail bleeding assay, in vitro and in vivo fibrinolysis inhibition assays, a thrombus formation assay and a plasminogen (PLG) electrophoresis assay.

show abstract

Section: V-7 Effect Of Cippc On Electrophoresis Of Uk and Plasminogenmentioning

confidence: 99%

From Cerius2 based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors

et al. 2011

View full text Add to dashboard Cite

show abstract

Thrombolytische Therapie im Kindesalter

Hertfelder

2010

Hämostaseologie

View full text Add to dashboard Cite

Alterations of fibrin network structure mediated by dermatan sulfate

Lauricella

Castañon

Kordich

et al. 2012

J Thromb Thrombolysis

View full text Add to dashboard Cite

Dermatan sulfate (DS) is well-known for its anticoagulant activity through binding to heparin cofactor II (HCII) to enhance thrombin inhibition. It has also been reported that DS has a profibrinolytic effect. We have evaluated the effects of DS solutions (4-20 μg/mL) on the formation (by kinetic studies), structure (by electron microscopy and compaction assays) and lysis (with urokinase-type plasminogen activator) of plasma fibrin networks. The results showed that DS significantly prolonged the lag phase and decreased the fibrin formation rate and the optical density of the final networks versus control, in a concentration dependent way. DS-associated networks presented a minor network percentage compared with control, composed of lower number of fibers per field, which resulted significantly thinner and longer. Moreover, DS rendered gels more sensible to rupture by centrifugal force and more susceptible to lysis. When fibrin formation kinetic assays were performed with purified fibrinogen instead of plasma, in the absence of HCII, the optical density of final DS-associated networks was statistically lower than control. Therefore, a direct effect of DS on the thickness of fibers was observed. Since in all in vitro assays low DS concentrations were used, it could be postulated that the fibrin features described above are plausible to be found in in vivo thrombi and therefore, DS would contribute to the formation of less thrombogenic clots.

show abstract

Insight into the profibrinolytic activity of dermatan sulfate: Effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators

Cited by 7 publications

References 43 publications

From Cerius2 based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors

From Cerius2 based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors

Thrombolytische Therapie im Kindesalter

Alterations of fibrin network structure mediated by dermatan sulfate

Contact Info

Product

Resources

About